Drug Trial Radar · NCT07332533
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Dec 30, 2025
Primary completion
Jun 30, 2032
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.
Conditions
- HER2-positive Gastric Cancer
Interventions
KN026Drug
In accordance with the protocol
CapecitabineDrug
Capecitabine is for oral administration.
EnlonstobartDrug
Enlonstobart is administered by intravenous infusion.
OxaliplatinDrug
Oxaliplatin is administered by intravenous infusion.
TrastuzumabDrug
Trastuzumab is administered by intravenous infusion.
PembolizumabDrug
Pembolizumab is administered by intravenous infusion.
CisplatinDrug
Cisplatin is administered by intravenous infusion.
FluorouracilDrug
Fluorouracil is administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by investigator in Phase IITime frame: Up to approximately 5 years
- Progression-Free Survival (PFS) by BIRC in Phase IIITime frame: Up to approximately 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.